Bicara Therapeutics (BCAX) Current Leases (2023 - 2026)

Bicara Therapeutics' Current Leases history runs 4 years deep, the most recent figure standing at $1.1 million for Q1 2026.

• In Q1 2026, Current Leases rose 92.89% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $1.1 million (up 92.89% YoY), while the FY2025 annual figure was $1.1 million, up 84.02% from the prior year.
• Current Leases for Q1 2026 stood at $1.1 million, up from $1.1 million in the prior quarter.
• The five-year high for Current Leases was $1.1 million in Q1 2026, with the low at $285000.0 in Q4 2023.
• The 4-year median for Current Leases is $840500.0 (2024), against an average of $777125.0.
• Peak annual rise in Current Leases reached 255.52% in 2025, while the deepest fall reached 84.02% in 2025.
• Bicara Therapeutics' Current Leases stood at $285000.0 in 2023, then jumped by 112.98% to $607000.0 in 2024, then jumped by 84.02% to $1.1 million in 2025, then increased by 2.06% to $1.1 million in 2026.
• Business Quant data shows BCAX's Current Leases at $1.1 million in Q1 2026, $1.1 million in Q4 2025, and $1.1 million in Q3 2025.